Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation

Recruiting now

Conditions studied: Atopic Dermatitis

In brief

Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy. The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.

Key facts

Study ID

NCT05098821

Run by

Charite University, Berlin, Germany

People needed

25

Starts

2019-10-01

Expected to finish

2026-12-31

Last updated by the study team

2024-08-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 and above
• Diagnosis of atopic dermatitis for ≥1 year
• Inadequate response to treatment with topical medications
• Confirmed dupilumab treatment

You may not qualify if…

• Age below 18
• Known or suspected allergy or reaction to any component of the dupilumab formulation
• Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of the severity of AD
• Severe conjunctivitis or blepharitis

Where it is running

• Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin — Berlin, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.